Medscape Medical NewsAll articles

HealthCXR

Zebra Medical Vision, Ltd. • Radiology • 11/26/2019

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

HealthCXR is an artificial intelligence-driven software tool designed to analyze adult chest X-rays for features suggestive of pleural effusion, aiming to enhance clinical workflow by prioritizing these cases for radiologist review. The system integrates with PACS/workstations to provide case-level alerts based on an algorithm validated to have high sensitivity and specificity, without making a diagnosis itself.

Summary

The HealthCXR device is a software-based workflow tool designed to assist in the clinical assessment of adult Chest X-Ray (CXR) images that may indicate pleural effusion. Utilizing an artificial intelligence algorithm, HealthCXR analyzes PA or AP chest X-rays to identify suspected findings. Once a potential case of pleural effusion is detected, the system provides a case-level notification to a Picture Archiving and Communication System (PACS) or workstation, facilitating worklist prioritization or triage. This allows clinicians to potentially review critical cases more quickly. The software operates in parallel with existing standard care workflows and includes modules for data input and validation, the pleural effusion detection algorithm, an IMA integration feature for communication with PACS/workstations, and an error coding system for failed analyses. It can also send notifications to a standalone desktop application, the Zebra Worklist, which includes a non-diagnostic preview image. The performance of HealthCXR was evaluated using a retrospective cohort of 554 anonymized CXR cases from the USA and Israel, comprising 276 cases positive for pleural effusion and 278 negative cases, with ground truth established by three U.S. Board-Certified Radiologists. The device achieved an Area Under the Curve (AUC) of 0.9885. Two operating points were defined: the first yielded a sensitivity of 96.74% and a specificity of 93.17%, while a second 'high-specificity' operating point demonstrated 93.84% sensitivity and 97.12% specificity. The mean processing time for image analysis and notification ranged from approximately 20 to 28 seconds. It is emphasized that HealthCXR is not intended for stand-alone diagnostic decision-making, nor to direct attention to specific image anomalies or to rule out pleural effusion; its role is strictly for prioritization within the medical care environment.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

HealthCXRPleural EffusionChest X-RayArtificial IntelligencePrioritization SoftwareTriagePACS IntegrationRadiologySensitivitySpecificity

Device Metadata

Submission Number
K192320
Company
Zebra Medical Vision, Ltd.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
triage

Relevant Clinical Questions

  • Q1. How does the HealthCXR AI algorithm differentiate features suggestive of pleural effusion from other potential lung pathologies or confounding image artifacts in chest X-rays?; What were the specific criteria used by the three U.S. Board-Certified Radiologists to establish the 'ground truth' for pleural effusion in the validation dataset?; How does the performance of HealthCXR (sensitivity, specificity, AUC) vary with different severities or extents of pleural effusion?; What mechanisms are in place within the 'Error codes feature' to ensure clinicians are adequately informed about the reasons for study failure during data validation or algorithm analysis?; Beyond the two described operating points, what is the continuous trade-off between sensitivity and specificity, and how were these specific points selected for clinical utility?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score30/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment✓ Detected in Summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(algorithm, dataset, ground truth)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials
- Not detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(environment)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
HealthCXR - Zebra Medical Vision, Ltd. | ESL FDA AI Device Intelligence